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Abstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders 
characterized by ineffective hematopoiesis, peripheral cytopenias, and a propensity for transfor-
mation to acute myeloid leukemia (AML). For many years, the main treatment option for MDS 
was best supportive care which alleviates symptoms but has no effect on the natural course of 
the disease. The recent approval of the demethylating agent azacitidine represents a significant 
advance in the treatment of MDS. The results of two randomized trials with azacitidine have 
shown an overall response rate between 40% and 60%, an improved quality of life, a reduced 
risk of transformation to AML and a definite survival advantage compared to best supportive 
care or low-dose chemotherapy. Current data on azacitidine and its place in the treatment of 
MDS are reviewed.
Keywords: myelodysplastic syndromes, MDS, azacitidine, epigenetic therapy, demethyltrans-
ferase inhibitor
Introduction
Myelodysplastic syndromes (MDS) encompass a group of hematopoietic stem cell 
malignancies characterized by ineffective hematopoiesis, peripheral cytopenias, and a 
propensity for transformation into acute myeloid leukemia (AML). The disease afflicts 
approximately 5 in every 100,000 individuals in the general population but incidence 
rises sharply with age, making MDS the most common hematologic cancer in the age 
group over seventy.1–3 With the exception of allogeneic stem cell transplantation, MDS 
remains incurable and most patients eventually die from their disease, most often due 
to infectious complications or transformation to AML.4 Thus, improving outcomes 
for patients with MDS remains an important goal in clinical hematology.
The prognosis for individual MDS patients varies greatly and ranges from rela-
tively indolent disease with longer life expectancy to more aggressive courses with 
rapid progression to overt leukemia. Prognosis depends on several factors, including 
the presence of chromosomal abnormalities, number of cytopenias, and percentage of 
bone marrow blasts as well as transfusion dependence. The most commonly employed 
score for prognostication in MDS is the risk-based International Prognostic Scoring 
System (IPSS).4 By combining blast percentage, karyotype, and number of cytope-
nias the IPSS provides a reliable estimate of survival and risk of transformation to 
AML for patients with MDS,4 although the prognostic importance of chromosomal 
abnormalities may be underestimated in this score. Using the IPSS, 4 distinctive risk 
groups can be identified which differ in terms of overall survival and AML evolution 
(low, intermediate-1, intermediate-2, and high risk). The IPSS can be combined Cancer Management and Research 2009:1 120
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with French-American-British (FAB) or World Health 
Organization morphologic criteria and additional variables 
such as the requirement for regular transfusions and serum 
LDH levels to further improve discrimination.5–7 MDS 
patients with a low or intermediate-1 IPSS score have a fairly 
favorable median survival of 5.7 and 3.5 years, respectively. 
In contrast, patients with higher-risk MDS (ie, Int-2 or high 
IPSS score) fare significantly worse with a median survival of 
1.2 or 0.4 years, respectively, and a high risk of progression 
to AML.4 MDS patients with lower-risk IPSS scores who 
are transfusion dependent also have a poor expected median 
overall survival.
In general, management of MDS depends on the IPSS 
score and transfusion requirement of the individual patient 
as well as age and comorbidities. The latter factors are espe-
cially relevant in the context of evaluation for allogeneic 
stem cell transplantation. Historically, the major goal of 
therapy for MDS patients with lower-risk disease (ie, IPSS 
low or Int-1 category) has been alleviation of symptoms and 
improvement in quality of life through correction of existing 
cytopenias, although prolonging survival is desirable as 
well. In contrast, the very poor prognosis of higher-risk 
MDS patients (ie, IPSS Int-2 or high-risk categories) makes 
extension of survival the major treatment objective in this 
subgroup. For these reasons, it has been common practice 
to stratify MDS patients according to IPSS risk into a 
lower-risk and a higher-risk group, respectively. However, 
as diagnosis of MDS subgroups becomes more refined 
through utilization of new molecular techniques and at the 
same time more effective therapies become available, the 
current stratification of risk groups as well as the therapeutic 
goals for these groups may have to be adapted. This review 
aims to summarize currently available therapeutic options 
for MDS patients with a particular focus on the role of the 
demethylating agent azacitidine.
Existing treatment options in MDS
For many years, the main treatment option for MDS was 
best supportive care (BSC) which aims to alleviate the 
negative effects of cytopenia and to increase quality of life. 
Even with the emergence of novel drugs, BSC remains the 
backbone of MDS therapy for all patients. This includes red 
blood cell transfusions to alleviate symptoms of anemia, 
platelet transfusions to decrease risk of hemorrhage in 
thrombocytopenic patients, adequate iron chelation therapy 
to reduce hemosiderosis, and control of infections by the 
use of antibiotics and granulocyte-colony stimulating factor 
(G-CSF) as appropriate.
In patients with lower-risk MDS, specific therapy 
beyond BSC should be considered if symptomatic cyto-
penia is present. For symptomatic anemia, treatment 
with erythropoiesis-stimulating agents (ESAs) such as 
erythropoietin or darbepoietin with or without the addition 
of G-CSF can be attempted in patients with a favorable 
response profile (ie, modest transfusion requirement and 
low erythropoietin serum levels).8,9 Patients suffering from 
isolated severe neutropenia and recurrent infections may 
benefit from use of G-CSF. Symptomatic thrombocytopenia is 
presently managed with platelet transfusions although throm-
bopoietin analogues may represent a therapeutic option in 
the future. For transfusion-dependent lower-risk patients with 
chromosome 5q deletion (del(5q)), the immunomodulatory 
agent lenalidomide is considered the primary treatment of 
choice as it has shown very high remission rates with achieve-
ment of transfusion independence.10,11 Lenalidomide may also 
be useful in the treatment of lower-risk MDS patients without 
del(5q) who do not respond to ESAs.12 Immunosuppressive 
therapy is an option for a very small subgroup of lower-risk 
MDS patients, especially younger patients with hypocellular 
bone marrow or HLA-DR15+ subtype and a low transfusion 
burden.13,14 While all of these treatment options may lead 
to improvement in blood values and an increased quality 
of life in patients with lower-risk MDS, a true survival 
benefit has so far been shown retrospectively for the use of 
erythropoietin + G-CSF only in the subgroup of patients with 
a low transfusion requirement.15,16
For higher-risk MDS patients, therapeutic options have 
been even more limited. Until recently there has been an 
absence of satisfactory treatment options bridging the 
gap between BSC on the one end and allogeneic stem cell 
transplantation (SCT) on the other end of the treatment 
spectrum. The only proven curative approach for MDS is 
allogeneic SCT,17–19 while other less intensive treatment 
strategies including non-intensive chemotherapy, immu-
nomodulatory agents or immunosuppressive therapy have 
not been able to change the natural course of the disease in 
higher-risk MDS patients.20 Allogeneic stem cell transplan-
tation has been shown to confer an overall survival benefit 
to patients with MDS with long-term event-free survival 
rates of 28% to 60%, depending on the IPSS score, transfu-
sion dependence and comorbidities.20–23 The most common 
approach is standard myeloablative conditioning, although 
reduced intensity conditioning is now also used more often, 
allowing older patients to undergo this procedure.18,19,24,25 
Transplant-related mortality is in the range of 30% to 40% 
in most studies and is a major cause of death, as is relapse Cancer Management and Research 2009:1 121
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after transplantation.26,27 Given these limitations as well as 
the prevalence of patients above the age of 70 years with 
considerable comorbidities, allogeneic SCT is not a realistic 
option for most patients with higher-risk MDS.
Demethylating agents such as azacitidine (Vidaza®; 
Celgene Corp., Summit, NJ, USA) and 5-aza-deoxycitidine 
(decitabine, Dacogen®; Eisai Inc., Woodcliff Lake, NY, 
USA) have recently emerged as promising drugs for the 
treatment of MDS. With proven efficacy in terms of remis-
sion rates as well as increased progression-free survival for 
all MDS subtypes and improved overall survival in higher-
risk MDS, azacitidine now represents the best alternative 
therapeutic option for those higher-risk MDS patients not 
eligible for allogeneic SCT. It may also be considered in 
transfusion dependent lower-risk MDS patients who have 
failed alternative therapies. Azacitidine was approved for the 
treatment of patients with MDS of all subtypes in 2004 by 
the US Food and Drug Administration (FDA) and for higher-
risk MDS, CMML and AML with 20% to 30% blasts and 
multi-lineage dysplasia by the European Medicines Agency 
(EMEA) in 2009.
DNA methylation and epigenetic 
therapy
Methylation of DNA is an epigenetic modification the cell 
uses to control certain processes such as gene transcription. 
In normal cells, much of the genome is methylated. DNA 
methylation patterns are specific for different tissues and are 
conserved through cell divisions, allowing the expression 
of the particular set of genes necessary for that cell type 
and inhibiting unchecked copying of repeat sequences.28 
Epigenetic modification of DNA is achieved by methylation 
of cytosine residues within CpG islands.29 These CpG islands 
located in the proximal gene promoter regions are short 
0.5 to 4 kb length regions rich in CpG dinucleotides. They 
are generally unmethylated in normal cells. Methylation of 
CpG islands changes the conformation of the chromatin, 
leading to inhibition of gene transcription and thus, gene 
silencing.29 In cancerous cells, DNA methylation is often 
lost or aberrantly increased, leading to abnormal gene 
expression. In particular, hypermethylation of CpG islands 
of tumor-suppressor genes is a common alteration in cancer 
cells.28,29 Methylation of DNA is accomplished by DNA 
methyltransferases (DNMTs) and elevated levels of DNMTs 
are commonly observed in human tumors.30
Among the tumor suppressor genes which have been 
shown to be epigenetically silenced in MDS are p15ink4b, 
which encodes a cyclin-dependent kinase inhibitor and 
CDH1, which encodes the adhesion molecule E-cadherin.31,32 
The presence of p15ink4b methylation is more frequent in 
higher-risk MDS and has been shown to correlate with 
disease progression.33–35 Similarly, methylation of CDH1 has 
been shown to have a negative prognostic impact in MDS, 
with inferior remission rates in response to chemotherapy in 
patients showing hypermethylation of this gene.36
The demethylating agents azacitidine and decitabine 
have been shown to act as DNMT inhibitors. Incorporation 
of azacitidine or decitabine into DNA results in a dose- and 
time-dependent inhibition of DNA methyltransferase activity 
by irreversible binding to the enzyme, thus preventing meth-
ylation of newly synthesized DNA. This allows a reversal of 
epigenetically silenced genes, restoring normal growth con-
trol and differentiation to impaired hematopoietic cells.29,37 
Accordingly, restoration of p15ink4b expression through 
hypomethylation has been demonstrated in bone marrow 
cells from MDS patients treated with decitabine.38 However, 
a second study failed to show a correlation between DNA 
demethylation of p15ink4b and clinical response to treatment 
with azacitidine, although lower baseline methylation was 
noted in responding patients.39
In addition to their demethylating properties, azacitidine 
as well as decitabine have been shown to induce direct 
cytotoxicity to cancer cells. However, the complete mode of 
action of either of these drugs has not yet been fully delin-
eated and is the subject of ongoing research.
Pharmacology of azacitidine 
and decitabine
Azacitidine (5-azacitidine) is an analogue of the naturally 
occurring pyrimidine nucleoside cytidine. Azacitidine 
differs from cytidine in containing a nitrogen atom at the 
5 position of the heterocyclic ring instead of a carbon atom 
(Figure 1). The chemical name of azacitidine is 4-amino-1-b-
D-ribofuranosyl-s-triazin-2(1H)-one, the empirical formula 
of azacitidine is C8H12N4O5 and the molecular weight is 244.40 
Azacitidine is a prodrug of 5-aza-deoxycitidine (decitabine). 
The chemical name of decitabine is 4-amino-1-(2-deoxy-b-
D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one. It has 
the molecular formula C8H12N4O4 and the molecular weight 
of 228.21.
Upon uptake into proliferating cells, azacitidine is 
phosphorylated to azacitidine monophosphate and then to 
diphosphate and triphosphate. The triphosphate metabolite is 
incorporated into RNA, leading to disruption of RNA metabo-
lism and consecutively to inhibition of protein synthesis. The 
diphosphate metabolite is further reduced to a deoxynucleotide Cancer Management and Research 2009:1 122
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in sterile water azacitidine is stable for up to 8 hours if 
refrigerated but must otherwise be administered within 
1 hour of preparation.40 After administration by subcutaneous 
or intravenous route, azacitidine is rapidly absorbed within 
10 to 30 minutes. The plasma half-life is 20 and 40 min-
utes for intravenous and subcutaneous administration, 
respectively.44 Azacitidine is widely distributed in tissues 
and eliminated primarily by urinary excretion. No studies 
on interactions between azacitidine and other drugs have 
been conducted.
Decitabine is also rapidly absorbed within 35 minutes 
and widely distributed in tissues. Decitabine crosses the 
blood–brain barrier achieving 27% to 58% of the plasma 
concentrations after continuous infusion.45 Decitabine is 
inactivated through its major elimination pathway by liver 
cytidine deaminase.42
Efficacy studies with azacitidine
Clinical data on the efficacy of azacitidine in the treatment of 
MDS are available from 2 phase II and 2 randomized phase III 
clinical trials.46–48 A total of 191 MDS patients were enrolled 
into the first phase III CALGB 9221 trial.46 Patients were 
randomized to receive BSC or azacitidine by subcutaneous 
injection at a dose of 75 mg/m2 on 7 consecutive days every 
28 days. All subtypes of MDS could be enrolled. However, 
patients with MDS subtypes RA/RARS were included only 
if they had severe thrombocytopenia or neutropenia or 
transfusion-dependent anemia. After a minimum of 4 months 
of supportive care, patients whose disease progressed were 
permitted to cross over to azacitidine treatment. A total of 99 
patients were primarily treated with azacitidine and an addi-
tional 49 patients (55% of patients in the observation arm) 
crossed over to azacitidine after 4 months. Approximately 
half of the total patient population had higher-risk MDS as 
determined by IPSS criteria. The primary endpoint of the 
study was overall response rate.
According to the International Working Group (IWG) 
criteria for assessing responses in MDS,49,50 the overall response 
rate in the azacitidine arm was 47% (Table 1).47 Responses to 
azacitidine were observed in all FAB subtypes. The majority 
of patients showed hematologic improvement while 11% 
achieved either a complete response (CR) or partial response 
(PR). There were no complete or partial remissions in the 
observation arm but 17% of patients also showed hematologic 
improvement under BSC. Patients treated with azacitidine 
showed a significant delay in progression to AML compared 
to the BSC arm (21 vs 13 months, P = 0.007). Improved sur-
vival by azacitidine treatment could not be established due to 
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Figure 1 Molecular structure of azacitidine, decitabine, and cytidine.
form (5-aza-deoxycitidine, decitabine) and then incorporated 
into DNA where it irreversibly binds and inhibits DNA 
methyltransferase.41,42 Decitabine is directly incorporated into 
DNA after activation by deoxycitidine kinase.43
Azacitidine is chemically unstable and therefore 
manufactured as a lyophilized powder. Upon reconstitution Cancer Management and Research 2009:1 123
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the crossover design and cohort size. However, an absolute 
difference in survival of 6 months in favor of azacitidine 
(20 months vs 14 months for BSC) was documented, 
suggesting a possible survival benefit.
Among the 99 patients randomized to azacitidine, 66% 
were transfusion dependent at baseline. Of these, 45% had 
an elimination of all transfusions while another 9% had 
a reduction in transfusions by 50%. In addition, lineage 
responses for platelets and white blood cells occurred in 
47% and 40%, respectively, among the patients treated with 
azacitidine. The median duration of transfusion independence 
was 9 months.
To definitely ascertain whether treatment with azaciti-
dine conferred a survival benefit to MDS patients, the large 
randomized phase III AZA-001 trial was initiated. This 
trial with the primary endpoint overall survival included 
358 patients with only higher-risk MDS (Int-2 or high-risk 
according to IPSS).48 Patients were randomized to receive 
either azacitidine (179 patients) at a dose of 75 mg/m2 
for 7 days or 1 of 3 conventional care regimens (CCR). 
The choice of conventional care regimens included BSC 
(105 patients), low-dose cytarabine (49 patients) or inten-
sive chemotherapy (25 patients) as selected by investiga-
tors before randomization. This trial showed a remission 
rate (CR + PR) of 29% for azacitidine compared to 12% 
for CCR (P  0.0001) and a hematological improvement 
rate of 49% for azacitidine compared to 29% for CCR 
(P  0.0001) (Table 2). Transfusion independence was 
achieved in 45% of patients receiving azacitidine who 
were dependent on red blood cell transfusions at base-
line. More importantly, a significantly prolonged median 
overall survival for the azacitidine group compared to 
the CCR group was demonstrated (24.5 vs 15.0 months, 
respectively, P = 0.0001) (Figure 2). In addition, time to 
AML progression as a secondary study endpoint was also 
significantly increased in the azacitidine arm (17.8 vs 
11.5 months, P  0.0001).
Thus, treatment with azacitidine prolongs overalls sur-
vival and lowers the risk of progression to AML in patients 
with higher-risk MDS. The absolute survival benefit for 
patients treated with azacitidine compared to conventional 
care was 9.4 months in the AZA-001 trial. The overall sur-
vival advantage at 2 years was 2-fold higher in the azaciti-
dine arm than the CCR arm (azacitidine: 51%; CCR: 26%; 
P  0.0001). The results of the randomized AZA-001 trial 
make azacitidine the first specific therapy to show a definite 
survival benefit for MDS patients in a prospective random-
ized study.
Comparison to decitabine
In contrast to results of the AZA-001 study for azacitidine, 
clinical trials for decitabine have thus far not been able 
to show an overall survival benefit in patients with MDS. 
Initial phase II trials in Europe using decitabine at a total 
dose of 225 mg/m2 as a continuous infusion over 72 hours 
or at a total dose of 135 mg/m2 using a 3-day intravenous 
administration over 4 hours 3 times a day showed a 
favorable overall response rate of 49% to 54%, comparable 
to that of azacitidine.51,52 In a randomized phase III trial 
testing decitabine in a schedule of 15 mg/m2 for a total 
of nine doses over 72 hours compared to BSC, the overall 
response rate was 30%.53 Patients with IPSS high-risk 
Table 1 Response to azacitidine (AZA) compared to best 
supportive care (BSC) in the randomized CALGB 9221 trial 
according to international  working Group (iwG) response criteria 
for MDS47
Response AZA 
(99 pts)
BSC 
(92 pts)
P value
CR (%) 10 0
PR (%) 1 0
Hi (%) 36 17
Total response rate (%) 47 17 0.001
Time to AML or death 
(months)
21 13 0.007
Transformation to AML 
as 1st event
15 38 0.001
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; PR, partial 
remission; Hi, hematologic improvement.
Table 2 Secondary endpoints in the AZA-001 trial comparing 
azacitidine (AZA) to conventional care regimens (CCR)
AZA CCR P value
Remission rate 
(CR + PR, %)
29 12 0.0001
Time to AML 
transformation 
(months)
26.1 12.4 0.004
Transfusion 
independence (%)
45 11 0.0001
Rate of infections 
requiring antibiotics
Reduced by 33% in AZA  
arm vs CCR arm
Reprinted from Lancet Oncol, 10, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy 
of azacitidine compared with that of conventional care regimens in the treatment 
of higher-risk myelodysplastic syndromes: a randomised, open-label, phase iii study, 
223–232,48 Copyright © 2009, with permission from elsevier. 
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; PR, partial 
remission.Cancer Management and Research 2009:1 124
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MDS receiving decitabine had a prolonged median time to 
progression to AML or death compared to patients receiving 
BSC but overall survival was not improved.53 Other clinical 
benefits of decitabine treatment were a reduction in growth 
factor and transfusion requirement and an increased quality 
of life.53 Recently published results of a schedule which can 
be administered in the outpatient setting using 20 mg/m2 
decitabine as intravenous infusion for 5 consecutive days 
yielded comparable clinical efficacy.54 The preliminary 
report of the recently completed randomized EORTC clinical 
trial comparing decitabine to BSC has also shown a benefit 
for progression-free survival but not for overall survival.55
The reasons for the discrepancy between azacitidine and 
decitabine in terms of survival benefit are unclear. One of the 
major differences in trial design was the number of treatment 
cycles administered. While treatment was continued until 
progression in the AZA-001 trial and a median of 9 cycles 
were administered, decitabine was administered for a maxi-
mum of only 6 cycles in the EORTC trial. Continuation of 
treatment therefore seems to be important to achieve maxi-
mum benefit. In addition, patient selection varied between 
the two trials. While the AZA-001 study enrolled patients 
on the basis of IPSS score (Int-2 and high-risk) and included 
patients with up to 30% bone marrow blasts, the EORTC 
study required patients to have either 10% to 20% blasts or 
unfavorable cytogenetics. The different dosing regimens as 
well as the length of each cycle of the two drugs could also 
play a role.56 The more direct metabolic activation pathway 
to DNA incorporation of decitabine compared to the primar-
ily RNA incorporation of azacitidine has been suggested to 
make decitabine a more potent compound than azacitidine. 
However, inhibition of DNA methyltransferase and hypo-
methylation may not be the only relevant mechanism for 
these drugs to elicit their clinical effect. Incorporation into 
RNA by azacitidine may also contribute to its anti-tumor 
effects. Further investigation in this area is necessary to 
understand the differences between these two demethylating 
agents. In addition, direct comparisons between azacitidine 
and decitabine are needed before conclusions about the rela-
tive efficacy of these two agents can be made.
Cytogenetics and response 
to azacitidine
Treatment with azacitidine also confers benefit in higher-risk 
MDS patients with cytogenetic abnormalities. There are vari-
ous recurring cytogenetic abnormalities frequently associated 
with MDS which confer a poor prognosis. This is especially 
true for alterations involving chromosome 7, either in the 
form of deletion (del (7q)) or absence (monosomy 7).5 
Complex aberrant karyotypes are also associated with inferior 
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Figure 2 Overall survival in the AZA-001 trial by intention-to-treat analysis.
Reprinted from Lancet Oncol, 10, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of 
higher-risk myelodysplastic syndromes: a randomised, open-label, phase iii study, 223–232,48 Copyright © 2009, with permission from elsevier. 
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outcome and are considered high risk whereas deletions of 
chromosome 20 (del(20q)) or isolated deletion of chromo-
some 5 (del(5q)) have a good prognosis.4,57 MDS patients with 
chromosome 7 abnormalities do not respond to conventional 
chemotherapy, making them poor candidates for intensive 
therapy if they are too old or frail to proceed to allogeneic stem 
cell transplantation.58 A high rate of remission in MDS patients 
with chromosome 7 abnormalities treated with azacitidine was 
first observed in a smaller uncontrolled study.39 In the random-
ized AZA-001 trial, treatment with azacitidine was shown to 
be beneficial for all cytogenetic subgroups of MDS including 
the group of patients with complex aberrations or chromosome 
7 abnormalities (Table 3).59 Overall survival in the subgroup 
of patients with chromosome 7 abnormalities was 13.1 months 
for the azacitidine arm vs only 4.6 months in the conventional 
care arm (P = 0.003).60 Thus, azacitidine extends survival for 
this subgroup of MDS patients with a very poor prognosis, for 
whom no real therapeutic options existed in the past. Patients 
with complex aberrant cytogenetics treated with azacitidine 
showed a similar survival benefit. Of note, decitabine has also 
been shown to be very active in patients with chromosome 
7 abnormalities.61 These favorable results suggest azacitidine or 
decitabine should be considered as therapy of choice in patients 
with chromosome 7 abnormalities or complex karyotypes ineli-
gible for allogeneic SCT. MDS patients with intermediate or 
good prognostic karyotypes also fared better under therapy with 
azacitidine than with CCR. The median overall survival for the 
azacitidine arm was not reached in the good risk subgroup and 
was 26.3 months in the intermediate risk subgroup compared 
to 17 months for both cytogenetic groups in the CCR arm 
(P = 0.04 and 0.02, respectively).48
Safety and tolerability of azacitidine
Since azacitidine is primarily excreted by the kidneys, the 
risk of toxicity is expected to be greater in patients with 
impaired renal function, although no formal studies have 
been performed. Likewise, the safety and pharmacokinetics 
of azacitidine have not been investigated in patients with 
evidence of hepatic impairment. It is therefore recommended 
that patients with renal or hepatic impairment be monitored 
closely. Azacitidine is contraindicated in patients with 
advanced malignant hepatic tumors. Azacitidine is potentially 
teratogenic. While this is not a concern for most elderly 
patients with MDS, women of childbearing potential should 
avoid becoming pregnant during therapy with azacitidine, 
and men should avoid fathering a child.
The most common adverse event occurring during treatment 
with azacitidine is myelosuppression. Since cytopenias are 
inherent to MDS, evaluation of treatment-induced myelo-
suppression is difficult to assess. However, low baseline 
blood cell counts further decreased in patients treated with 
azacitidine. Accordingly, the most common reasons for treat-
ment discontinuation, dose reduction or interruption were 
leukocytopenia, neutropenia and thrombocytopenia. In the 
CALGB 9221 trial, grade 3–4 leukocytopenia occurred in 
59%, granulocytopenia in 81% and thrombocytopenia in 
70% of patients receiving azacitidine.46 Infection thought to 
be related to treatment was reported in 20% of patients. The 
highest rate of adverse events was reported during the first 
2 cycles of therapy and decreased in subsequent cycles. The 
proportion of patients with adverse events did not increase 
with patient age. There was 1 treatment-related death 
(1%) in the CALGB 9221 trial and 4 treatment-related 
deaths (2%) in the AZA-001 trial. In the AZA-001 trial, 
rates of grade 3–4 toxicity were 91% for neutropenia, 85% 
for thrombocytopenia and 57% for anemia.48 Five percent 
of patients receiving azacitidine discontinued treatment 
in the AZA-001 trial before study completion owing to 
hematological adverse events.
Non-hematological adverse events were most commonly 
either gastrointestinal or associated with administration. 
Injection site reactions in the form of localized erythema 
or bruising occur in almost all patients with subcutaneous 
application of azacitidine. Generally, these reactions are 
Table 3 Median overall survival in AZA-001 trial according to cytogenetic risk
Cytogenetic risk group % pts (n/N) Median overall survival 
(months)
HR (95% CI) P value 
log rank
AZA CCR
Good (normal, del(5q), del(20q) 46 (166/358) Not reached 17.1 0.61 (0.39–0.96) 0.030
intermediate (other) 21 (76/358) 26.3 17.0 0.43 (0.21–0.88) 0.017
Poor (complex, –7) 28 (100/358) 17.2 6.0 0.52 (0.32–0.87) 0.011
Reprinted from Lancet Oncol, 10, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of 
higher-risk myelodysplastic syndromes: a randomised, open-label, phase iii study, 223–232,48 Copyright © 2009, with permission from elsevier. 
Abbreviations: AZA, azacitidine; CCR, conventional care regimens; CI, confidence interval; HR, hazard ratio.Cancer Management and Research 2009:1 126
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transient and do not require specific therapy. Common 
gastrointestinal side effects include nausea, vomiting, diarrhea, 
constipation and anorexia. Table 4 summarizes the most 
common side effects during azacitidine treatment and their 
management. Other reported less common adverse events were 
arthralgia, cough, headache, weakness, dizziness and insomnia. 
Liver function abnormalities occurred in patients with 
intercurrent illnesses and more severe abnormalities were 
noted in patients with liver cirrhosis.44 Adverse events occurred 
at about the same frequency in males and females and in all 
age groups.40 Treatment of older patients 75 years was not 
associated with increased toxicity.62
Dosing of azacitidine and duration 
of therapy
The standard dosing regimen for azacitidine employed in 
the CALGB 9221 as well as the AZA-001 trial is 75 mg/m2 
for 7 consecutive days repeated every 28 days (AZA-7). 
Patients should be premedicated for nausea and vomiting. 
For the most part, administration of metoclopramide or 
alizapride prior to azacitidine is sufficient. However, in 
some cases nausea may be more severe and additional 
antiemetic medication such as a 5-HT3 antagonist may be 
required. Azacitidine can be administered subcutaneously 
or by intravenous route, although it is licensed in Europe 
for subcutaneous application only. The starting dose of 75 
mg/m2 is recommended regardless of baseline blood values. 
Since the 7-day regimen can be cumbersome in the outpa-
tient setting, alternative schedules, either skipping weekends 
(AZA-5-2-2) or administering azacitidine for only 5 days 
(AZA-5) have been proposed. Recently published data from 
an open-label randomized phase II trial have demonstrated 
equal efficiency of these two schedules with the established 
7-day schedule,63 although overall survival was not a study 
endpoint. On a cautionary note however, the majority of 
patients (63%) included in this trial had lower-risk MDS. The 
use of the AZA-5 schedule results in a 30% dose reduction 
compared to the AZA-7 schedule. Though toxicity in terms 
of grade 3–4 hematologic adverse events was lower using 
the AZA-5 than the AZA-5-2-2 regimen,63 it is conceivable 
that a decreased dose may also translate into reduced effi-
cacy in higher-risk MDS patients. Therefore, the use of the 
AZA-5 schedule cannot be routinely recommended in the 
higher-risk setting. For patients with lower-risk MDS and 
transfusion dependence who are candidates for azacitidine, 
the AZA-5 regimen is an appropriate choice based on its 
superior tolerability.63
Due to its mode of action of promoting demethylation 
in newly synthesized DNA, several rounds of DNA rep-
lication are necessary before azacitidine can elicit its full 
clinical effect.64–66 In the CALGB 9221 trial, the median 
number of cycles from the first treatment with azacitidine 
to response was 3 cycles (range, 1 to 17 cycles).47 Although 
75% of responding patients achieved a response by cycle 4, 
one-fourth of responding patients showed an effect as late as 
cycle 17. The majority of responding patients (90%) achieved 
a response by the sixth cycle. On average, best response 
was observed 2 cycles after initial response. Similarly, in 
the AZA-001 trial the median number of cycles until first 
response was 3, with 50% of responding patients showing 
an effect after 2 courses and 87% of patients achieving a 
response by cycle six.67 Best response was achieved after a 
median of 4 cycles. On the basis of these results, it becomes 
evident that terminating therapy if no response is seen after 
a few cycles would be premature and prevent many patients 
from benefiting from azacitidine treatment. There is an 
Table 4 Common side effects of azacitidine and their management
Side effect Management Medication
Hematologic (neutropenia, 
thrombocytopenia, anemia)
Routine monitoring of CBC 
Delay administration of next cycle until 
hematologic recovery 
Dose reduction if necessary
Transfusions (RBC and platelets),
consider G-CSF, consider prophylactic antibiotics 
(ie, quinolones)
infections Monitor clinically for signs of infection 
Consider prophylaxis in neutropenic pts
Prompt initiation of antibiotic therapy,
consider G-CSF
Nausea, vomiting Symptomatic Alizapride or metoclopramide 5-HT3-antagonist 
if more severe nausea present
Diarrhea Symptomatic Fluid substitution, loperamide
Constipation Symptomatic Laxatives
injection site reaction Symptomatic Cool compresses,  antihistamines, steroids
Abbreviations: CBC, complete blood count; RBC, red blood cells; G-CSF, granulocyte-colony stimulating factor.Cancer Management and Research 2009:1 127
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emerging consensus to treat MDS patients with azacitidine 
for a minimum of 6 cycles before evaluating response unless 
overt progression to AML or unacceptable toxicity occurs.
Another presently unresolved issue is the optimal duration 
of azacitidine therapy. In the CALGB 9221 trial, the range 
of cycles was 1 to 17 but a median cycle number was not 
stated.46 Best response lasted for a median of 5 cycles after 
achievement of first response.47 In the AZA-001 study, cycle 
range was 1 to 39 with a median of 9 cycles.48 Continuation 
of azacitidine therapy led to a higher IWG response category 
in 43% of responding patients and these patients received 
a median of 8 additional azacitidine courses.67 The median 
duration of hematological response (CR, PR or any hemato-
logic improvement) in the AZA-001 trial was 13.6 months. 
In a small retrospective study, the outcome of patients with 
higher-risk MDS treated with a limited number of azacitidine 
cycles was analyzed.68 Patients were treated for a median of 
4 cycles, with only 2 additional cycles administered as con-
solidation if a response was achieved after 4 cycles. Although 
patients clearly benefited even from this limited number of 
treatment courses, remission rates were lower and median 
survival was inferior to the AZA-001 trial where treatment 
was continued until progression.
The distinct mechanism of action of 5-azacitidine infers 
continuing benefit with prolonged therapy, and indeed this 
seems to be borne out by the results of the two randomized 
phase III trials. However, the optimal duration of therapy 
has not been clearly defined. In the absence of unacceptable 
toxicity, continued azacitidine treatment seems appropriate 
in responding patients and may maximize patient benefit. 
Of note, achievement of complete remission is not a 
prerequisite for attaining a survival benefit with azaciti-
dine in higher-risk MDS. As further analyses of patient 
subgroups in the AZA-001 trial have shown, even hemato-
logic improvement as defined by the IWG criteria confers 
an overall survival advantage for patients treated with 
azacitidine.69 In this analysis, one year survival was improved 
with azacitidine compared to conventional care in all IWG 
response categories. These results call into question the 
current paradigm that achievement of complete remission 
is necessary to prolong survival in MDS.50
Relapse following azacitidine 
treatment
A frequent problem for MDS patients treated with azaciti-
dine is relapse or disease progression some time after 
discontinuation of therapy. At this time, there are insufficient 
data to draw definite conclusions on re-treating patients with 
azacitidine at relapse. However, anecdotal reports suggest 
this is feasible, although responses to renewed treatment 
seem to be inferior in terms of both quality of remission and 
duration of response.70
Patient-focused outcomes
In the randomized CALGB 9221 and AZA-001 trials, patient-
focused outcomes such as quality of life were independently 
assessed. A significantly improved quality of life for those 
MDS patients treated with 5-azacitidine as compared to 
conventional care was documented for both trials.71,72 This 
was evidenced by the reduction in transfusion requirements, 
decreased rate of infections and hospitalizations as well as 
improvement of fatigue, dyspnea, and physical functioning 
in patients receiving azacitidine. In our own experience, 
patients may have a temporary increase in fatigue during 
the first 2 cycles of therapy. However, as azacitidine exerts 
its effect, fatigue and asthenia decrease and patients report 
improved physical functioning and sense of well-being with 
continued therapy. Azacitidine is generally well-tolerated 
with few side effects. Therefore, patients’ acceptance of 
this treatment is usually high. However, continuation of 
azacitidine treatment may become an issue for patients after 
a prolonged period of therapy, especially if only stable dis-
ease has been achieved and treatment success is not obvious. 
The decision to continue azacitidine therapy in patients with 
stable disease should be at the treating physician’s discretion 
and take into account whether or not the patient is motivated 
to continue therapy. Patients who achieve hematologic 
improvement, PR or CR with acceptable toxicity under 
azacitidine therapy should be urged to continue treatment 
to maximize their benefit.
Conclusions
The approval of the demethylating agents azacitidine and 
decitabine for the treatment of MDS with higher-risk disease 
represents a significant advance for this group of patients, 
for whom treatment options have been very limited in the 
past. Approximately 50% of higher-risk MDS patients can 
be expected to respond to azacitidine with improvement of 
peripheral blood values, reduction in transfusion requirement 
and increased quality of life. Moreover, time to progression 
to AML is prolonged and overall survival significantly 
increased by treatment with azacitidine. Side effects are gen-
erally predictable and manageable by simple prophylactic 
measures. Based on these favorable clinical trial results, 
epigenetic therapy with azacitidine can be regarded as the 
primary therapy of choice for patients with higher-risk MDS Cancer Management and Research 2009:1 128
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not eligible for allogeneic SCT. In patients with lower-risk 
MDS, azacitidine has also produced significant response 
rates with achievement of transfusion independence in 
over 50% of cases. Therefore, azacitidine is an attractive 
additional therapeutic option for patients with lower-risk 
MDS who are transfusion dependent and have failed other 
therapies. Future applications include using azacitidine as 
a bridge to allogeneic stem cell transplantation as well as 
for post-transplant relapses and combining azacitidine with 
other novel drugs to further improve outcomes in patients 
with MDS.
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